News & Articles

Oxford Brain Diagnostics and Memory Treatment Centers (Bonita Springs and Jacksonville, Florida), establish a research collaboration to explore Alzheimer’s disease in subjects who are cognitively impaired and receiving anti-amyloid treatment. As the global Alzheimer’s community enters a new era of drug treatments for Alzheimer’s patients,

U.S. FDA Grants Traditional Approval to Leqembi (Lecanemab-Irmb) for Alzheimer’s Disease Treatment. BONITA SPRINGS, FL July 6, 2023 – FDA Grants Traditional Approval to Leqembi (Lecanemab-Irmb) for Alzheimer’s Disease Treatment. In a groundbreaking move, Leqembi has received traditional approval from the FDA for the treatment

Memory Treatment Centers at the forefront of Alzheimer’s treatment innovation, as featured in the Wall Street Journal Memory Treatment Centers neurologist, Jamie Plante and current Leqembi patient were interviewed by the Wall Street Journal to investigate availability of new Alzheimers treatments. With the recent FDA

Memory Treatment Centers, a leading neurocognitive disease clinic, is proud to be one of the first medical organizations in the United States to offer the innovative Alzheimer’s drug Leqembi (lecanemab-irmb). Bonita Springs, FL February 6, 2023 – Last week, Memory Treatment Centers (MTC) became amongst

Memory Treatment Centers Applauds U.S. FDA Approval of Leqembi (Lecanemab) BONITA SPRING, FL, January 10, 2023 —  Memory Treatment Centers are pleased to announce that the Food and Drug Administration (FDA) has approved Lecanemab, a new drug for the treatment of Alzheimer’s disease. This is an